Home > Search Results

Results: 1 to 20 of 85

Clear

Memantine is thought to improve cognitive function and slow the decline of AD over time.The effects of memantine on AD are reported to be beneficial for people with moderate to severe AD in the general population, However, people with DS tend to present with AD at a much younger age than the general population as well as being physically different in terms of size, metabolism and heart rate, and may therefore have different requirements. Results from the one randomised controlled trial for the treatment of dementia in DS are not yet available (expected 2009).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: January 21, 2009

The research question of the present investigation is as follows: What is the impact of the responder analyses calculated post hoc by Merz and submitted to the G-BA in the fourth quarter of 2010 on the conclusions of the final report A05-19C (“Memantine in Alzheimer’s disease”)?

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: March 28, 2011

Memantine has a small beneficial, clinically detectable effect on cognitive function and functional decline measured at 6 months in patients with moderate to severe Alzheimer's Disease (AD). In patients with mild to moderate dementia, the small beneficial effect on cognition was not clinically detectable in those with vascular dementia and barely detectable in those with AD. It is well tolerated. Slightly fewer patients with moderate to severe AD taking memantine develop agitation, but there is no evidence either way about whether it has an effect on agitation which is already present.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: April 19, 2006

The aims of the present investigation were: to assess the benefit of long-term treatment with memantine for Alzheimer’s disease compared to placebo with regard to patient-relevant outcomes to assess the benefit of long-term treatment with memantine for Alzheimer’s disease compared to treatment with a different drug or non-drug therapy option with regard to patient-relevant outcomes.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 8, 2009

Alzheimer's disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK.

Health Technology Assessment - NIHR Journals Library.

Version: April 2012

Bibliographic details: Soares Araujo R, Pereira Ponde M.  [Efficacy of memantine in moderate to severe Alzheimer disease]. [Eficacia da memantina na doenca de Alzheimer em seus estagios moderado a grave .] Jornal Brasileiro de Psiquiatria 2006; 55(2): 148-153

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Alzheimer's disease (AD) is the most common cause of dementia and is characterised by an insidious onset and slow deterioration in cognition, functional ability (e.g. activities of daily living) and behaviour and mood. AD prevalence rises with increasing age and the estimated prevalence of AD for a standard primary care trust with a population of 200,000 is approximately 1100. Current service involves a wide range of agencies. In 2001, the National Institute for Health and Clinical Excellence (NICE) recommended that cholinesterase inhibitors (donepezil, rivastigmine, galantamine) should be offered to patients with mild to moderate AD under a number of conditions. Patients with more severe AD may benefit from memantine but there is currently no guidance on its use.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2006

Alzheimer’s disease (AD) is the most commonly occurring form of dementia, accounting for approximately 62% of instances of dementia. AD is predominantly a disease of later life, with 5% of the UK population over 65 years affected. In England and Wales, among people aged 65–69 years, the incidence is estimated to be 7.4 [95% confidence interval (CI) 3.6 to 16.1] per 1000 person-years, rising to 84.9 (95% CI 63.0 to 107.8) per 1000 person-years at 85 years old and above. These rates predict 180,000 new cases of dementia per year and, if 62% of these have AD (see above), then there are approximately 111,600 new cases in England and Wales per year.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2012

Bibliographic details: Chen YC, Zhou XH, Su R, Liu Y.  Efficacy and safety of memantine versus donepezil for Alzheimer's disease: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012; 12(2): 209-213 Available from: http://www.cjebm.org.cn/en/oa/DArticle.aspx?type=view&id=201202014

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Bibliographic details: Lopez Arrieta JM.  [Efficacy of memantine in improving activities of daily living in patients with Alzheimer's disease]. [Beneficios clinicos de la memantina en las alteraciones de la capacidad para realizar actividades de la vida diaria en pacientes con enfermedad de Alzheimer: revision sistematica de la bibliografia medica.] Revista Espanola de Geriatria y Gerontologia 2006; 41(3): 183-189 Available from: http://zl.elsevier.es/es/revista/revista-espanola-geriatria-gerontologia-124/resumen/beneficios-clinicos-memantina-las-alteraciones-13088490

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

BACKGROUND/AIMS: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Problems with mental activities (cognitive deficits) are common in patients who have received radiation to the brain for a primary or secondary (metastatic) brain tumour, or to help prevent a tumour spreading to the brain from elsewhere in the body. This toxic side effect of brain radiation may be acute (during treatment) or early after treatment (one to six months) and may be reversible. However, late toxicities may occur many months or years later and are generally irreversible and are slowly progressive. Late cognitive deficits, such as memory loss, problems planning tasks or behavioural changes, can have a serious impact on quality of life and the ability to carrying out activities normally. Interventions to help prevent or treat these late radiation toxicities may improve a patient's well‐being.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: December 18, 2014

BACKGROUND/OBJECTIVE: Memantine is approved as a treatment for moderate to severe Alzheimer's disease (AD). However, recent studies report that memantine is harmful for AD patients in several ways. This paper will systematically review all the available studies to provide an update regarding memantine as a treatment for AD.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

INTRODUCTION: Memantine is currently the only treatment approved for moderately severe to severe Alzheimer's disease (AD). There is still some discussion as to its place in clinical practice and many UK clinicians are discouraged for economic reasons from prescribing it. We adopt a 'number needed to treat' (NNT) approach to assess the benefits reported in memantine trials.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

BACKGROUND: We performed an updated meta-analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

People with Down syndrome often experience cognitive decline (a deterioration in memory, language, thinking and judgment that are greater than normal age‐related changes) at a younger age and in greater numbers than the general population. Various medicines have been shown to improve, or at least slow down the progression of these symptoms in people without Down syndrome.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: October 29, 2015

INTRODUCTION: in 2007 the National Institute of Health and Clinical Excellence (NICE) restricted the use of acetylcholinesterase inhibitors and memantine.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: December 17, 2013

OBJECTIVE: To clarify whether memantine is more efficacious in several outcomes and safer than placebo in patients with Lewy body disorders, we performed a meta-analysis of memantine in patients with Lewy body disorders.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

BACKGROUND: Cholinesterase inhibitors and memantine do not have regulatory approval in most of the world for treatment of vascular dementia. A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular dementia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Systematic Reviews in PubMed

See all (233)...

Systematic Review Methods in PubMed

See all (5)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...